price
GL
NASDAQ · GLUE
Monte Rosa Therapeutics, Inc.
Healthcare · Biotechnology
$12.60
Down-$0.05 (-0.40%)
Updated Sep 18, 2026, 2:48 AM
SID Score
3.4/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.08B
- P/E ratio
- 56.25
- Dividend yield
- 0.00%
- 52-week range
- $6.25 – $25.77
- Volume
- 1.39M
- Avg. volume
- 1.57M
Price performance
GLUE price history
1M range · 20 trading sessions · Daily adjusted prices
GLUE closed at $12.60 after 20 trading sessions, down 14.75% for the selected period.
- Last close
- $12.60
- Period change
- -14.75%
- Period low
- $12.60
- Period high
- $14.78
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 17, 2026 | $12.84 | $13.02 | $12.43 | $12.60 | 1.39M |
| Sep 16, 2026 | $12.94 | $13.01 | $12.59 | $12.65 | 1.5M |
| Sep 15, 2026 | $13.84 | $13.88 | $12.87 | $12.99 | 1.27M |
| Sep 14, 2026 | $14.35 | $14.38 | $13.38 | $13.90 | 1.79M |
| Sep 11, 2026 | $14.235 | $14.74 | $13.88 | $14.07 | 1.17M |
| Sep 10, 2026 | $14.21 | $14.34 | $13.83 | $14.32 | 1.06M |
| Sep 9, 2026 | $14.28 | $14.87 | $14.13 | $14.26 | 1.15M |
| Sep 8, 2026 | $13.55 | $14.29 | $13.44 | $14.27 | 1.2M |
| Sep 4, 2026 | $14.12 | $14.31 | $13.79 | $13.84 | 804.59K |
| Sep 3, 2026 | $14.50 | $14.59 | $14.06 | $14.38 | 672.73K |
| Sep 2, 2026 | $14.38 | $15.00 | $13.81 | $14.22 | 1.53M |
| Sep 1, 2026 | $13.81 | $14.32 | $13.71 | $14.31 | 796.29K |
| Aug 31, 2026 | $13.39 | $14.11 | $13.12 | $13.94 | 1.11M |
| Aug 28, 2026 | $14.29 | $14.30 | $13.37 | $13.38 | 884.65K |
| Aug 27, 2026 | $14.28 | $14.57 | $14.19 | $14.32 | 1.08M |
| Aug 26, 2026 | $14.44 | $14.6248 | $14.10 | $14.38 | 997.72K |
| Aug 25, 2026 | $14.06 | $14.8399 | $14.00 | $14.56 | 1.1M |
| Aug 24, 2026 | $14.03 | $14.29 | $13.29 | $13.775 | 2M |
| Aug 21, 2026 | $14.80 | $15.00 | $14.17 | $14.30 | 969.16K |
| Aug 20, 2026 | $15.62 | $15.90 | $14.715 | $14.78 | 1.02M |
Latest GLUE news
The latest Smart Investors Daily articles mentioning GLUE.
Stock researchResearch & News · SEC Filings
Loading stock research…